

FORM PTO-1449

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000D/EJH/SJEAPPLICATION NO.
10/774,622FIRST NAMED INVENTOR
Ni et al.FILING DATE
February 10, 2004ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
CK	AT	33	Australian Opposition Document, EVIDENCE IN SUPPORT: Statutory Declaration of Andreas Strasser dated 7 April 2005 together with Exhibits AS-10 to AS-23, submitted by Genentech, Inc. in the Opposition to Australian Patent Application 747635 (67635/98), 467 pages (April 7, 2005) -----DO NOT PRINT-----

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000D/EJH/SJEAPPLICATION NO.
10/774,622FIRST NAMED INVENTOR
Ni et al.FILING DATE
February 10, 2004ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	34	Australian Opposition Document, EVIDENCE IN SUPPORT: Statutory Declaration of David Vaux dated 12 April 2005 together with Exhibits DLV-8 to DLV-20, submitted by Genentech, Inc. in the Opposition to Australian Patent Application 747635 (67635/98), 412 pages (April 12, 2005) -----DO NOT PRINT-----
CK	AS	34	Australian Opposition Document, EVIDENCE IN SUPPORT: Statutory Declaration of Simon Tout dated 14 April 2005 together with Exhibits SDT-1 to SDT-3, submitted by Genentech, Inc. in the Opposition to Australian Patent Application 747635 (67635/98), 328 pages (April 14, 2005) -----DO NOT PRINT-----
	AT		

EXAMINER /Claire Kaufman/

DATE CONSIDERED 09/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

NOV 04 2005
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Claire Kaufman/	Date Considered	09/14/2006
-----------------------	------------------	--------------------	------------

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

02/10/04

Page 1 of 14

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1488.131000D/EKS/EJH/SJEAPPLICATION NO.
~~To be assigned~~ 10/774,622FIRST NAMED INVENTOR
Jian NiFILING DATE
February 10, 2004ART UNIT
~~To be assigned~~ 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
CK	AA1	4,002,531	01/11/1977	Royer	195	68	01/22/1976
	AB1	4,946,778	08/07/1990	Ladner <i>et al.</i>	435	69.6	01/19/1989
	AC1	5,349,053	09/20/1994	Landolfi	530	351	06/10/1993
	AD1	5,447,851	09/05/1995	Beutler <i>et al.</i>	435	69.7	04/02/1992
	AE1	5,478,925	12/26/1995	Wallach <i>et al.</i>	530	351	08/07/1992
	AF1	5,530,101	06/25/1996	Queen <i>et al.</i>	530	387.3	12/19/1990
	AG1	5,565,332	10/15/1996	Hoogenboom <i>et al.</i>	435	69.1	09/23/1994
	AH1	5,643,575	07/01/1997	Martinez <i>et al.</i>	424	194.1	10/27/1993
	AI1	5,763,223	06/09/1998	Wiley <i>et al.</i>	435	69.5	06/25/1996
	AJ1	5,807,715	09/15/1998	Morrison <i>et al.</i>	435	69.6	06/27/1994
CK	AK1	6,072,047	06/06/2000	Rauch <i>et al.</i>	536	23.5	06/26/1997

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
CK	AL1	EP 0 239 400 B1	09/30/1998	Europe			Yes
	AM1	EP 0 401 384 B1	12/12/1990	Europe			No
	AN1	WO 91/06570	05/16/1991	WIPO			Yes
	AO1	WO 91/09967	07/11/1991	WIPO			No
CK	AP1	CA 2045869	12/29/1991	Canada			Yes

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	1	Chaudhary, P.M., <i>et al.</i> , "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF- κ B Pathway," <i>Immunity</i> 7:821-830, Cell Press (December 1997).
CK	AS	1	Chinnaiyan, A.M., <i>et al.</i> , "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95," <i>Science</i> 274:990-992, American Association for the Advancement of Science (November 1996).
CK	AT	1	Delgado, C., <i>et al.</i> , "The Uses and Properties of PEG-Linked Proteins," <i>Crit. Rev. Ther. Drug Carrier Sys.</i> 9:249-304, CRC Press, Inc. (1992).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000D/EKS/EJH/SJEAPPLICATION NO.
*To be assigned*FIRST NAMED INVENTOR
Jian NiFILING DATE
February 10, 2004ART UNIT
*To be assigned***U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
CK	AA2	6,313,269 B1	11/06/2001	Deen <i>et al.</i>	630	350	06/15/1999
CK	AB2	6,342,369 B1	01/29/2002	Ashkenazi	435	69.1	05/14/1998
CK	AC2	6,569,642 B1	05/27/2003	Rauch <i>et al.</i>	435	69.1	03/27/2000
	AD2						
	AE2						
	AF2						
	AG2						
	AH2						
	AI2						
	AJ2						
	AK2						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
CK	AL2	EP 0 510 691 A1	10/28/1992	Europe			Yes
	AM2	WO 94/01548	01/20/1994	WIPO			No
	AN2	WO 95/06058	03/02/1995	WIPO			Yes
	AO2	WO 98/32856	07/30/1998	WIPO			No
CK	AP2	WO 98/35986	08/20/1998	WIPO			Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	2	Huston, J.S., <i>et al.</i> , "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins," <i>Meth. Enzymol.</i> 203:46-88, Academic Press, Inc. (1991).
CK	AS	2	Marsters, S.A., <i>et al.</i> , "A novel receptor for APO2L/Trail contains a truncated death domain," <i>Curr. Biol.</i> 7:1003-1006, Current Biology Ltd. (December 1997).
CK	AT	2	Morpurgo, M., <i>et al.</i> , "Covalent Modification of Mushroom Tyrosinase with Different Amphiphilic Polymers for Pharmaceutical and Biocatalysis Applications," <i>Appl. Biochem. Biotechnol.</i> 56:59-72, Humana Press Inc. (January 1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000D/EKS/EJH/SJEAPPLICATION NO.
*To be assigned*FIRST NAMED INVENTOR
Jian NIFILING DATE
February 10, 2004ART UNIT
*To be assigned***U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3						
	AB3						
	AC3						
	AD3						
	AE3						
	AF3						
	AG3						
	AH3						
	AI3						
	AJ3						
	AK3						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
CK ↓ CK	AL3	EP 0 870 827 A2	10/14/1998	Europe			Yes
	AM3	WO 99/02653	01/21/1999	WIPO			No
	AN3	WO 98/46643 A1	10/22/1998	WIPO			Yes
	AO3	WO 98/51793 A1	11/19/1998	WIPO			No
	AP3	WO 99/00423 A1	01/07/1999	WIPO			Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>3</u>	Morrison, S.L., "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> 229:1202-1207, American Association for the Advancement of Science (1985).
CK	AS	<u>3</u>	Pan, G., <i>et al.</i> , "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> 276:111-113, American Association for the Advancement of Science (April 1997).
CK	AT	<u>3</u>	Pan, G., <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> 277:815-818, American Association for the Advancement of Science (August 1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

CK

Page 4 of 14

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/SJE	APPLICATION NO. <i>To be assigned</i>
	FIRST NAMED INVENTOR Jian Ni	
	FILING DATE February 10, 2004	ART UNIT <i>To be assigned</i>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA4						
	AB4						
	AC4						
	AD4						
	AE4						
	AF4						
	AG4						
	AH4						
	AI4						
	AJ4						
	AK4						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL4						Yes
							No
	AM4						Yes
							No
	AN4						Yes
							No
	AO4						Yes
							No
	AP4						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	4	Rieger, J., et al., "APO2 ligand: a novel lethal weapon against malignant glioma?" <i>FEBS Lett.</i> 427:124-128, Federation of European Biochemical Societies (May 1998).
CK	AS	4	Roguska, M.A., et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing," <i>Proc. Natl. Acad. Sci. USA</i> 91:969-973, National Academy of Sciences (1994).
CK	AT	4	Schneider, P., et al., "TRAIL Receptors 1 (DR4) and 2 (DR5) Signal FADD-Dependent Apoptosis and Activate NF- κ B," <i>Immunity</i> 7:831-836, Cell Press (December 1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/SJE	APPLICATION NO. <i>To be assigned</i>
	FIRST NAMED INVENTOR Jian NI	
	FILING DATE February 10, 2004	ART UNIT <i>To be assigned</i>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA5						
	AB5						
	AC5						
	AD5						
	AE5						
	AF5						
	AG5						
	AH5						
	AI5						
	AJ5						
	AK5						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL5						Yes No
	AM5						Yes No
	AN5						Yes No
	AO5						Yes No
	AP5						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>5</u>	Sheikh, S.M., <i>et al.</i> , "p53-dependent and -independent Regulation of the Death Receptor <i>KILLER/DR5</i> Gene Expression in Response to Genotoxic Stress and Tumor Necrosis Factor α ," <i>Cancer Res.</i> 58:1593-1598, American Association for Cancer Research (April 1998).
CK	AS	<u>5</u>	Sheridan, J.P., <i>et al.</i> , "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," <i>Science</i> 277:818-821, American Association for the Advancement of Science (August 1997).
CK	AT	<u>5</u>	Uhlén, M., <i>et al.</i> , "Fusion proteins in biotechnology and structural biology," <i>Curr. Opin. Biotechnol.</i> 3:363-369, Current Biology Ltd. (1992).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/SJE	APPLICATION NO. <i>To be assigned</i>
	FIRST NAMED INVENTOR Jian Ni	
	FILING DATE February 10, 2004	ART UNIT <i>To be assigned</i>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA6						
	AB6						
	AC6						
	AD6						
	AE6						
	AF6						
	AG6						
	AH6						
	AI6						
	AJ6						
	AK6						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
	AL6						No
							Yes
	AM6						No
							Yes
	AN6						No
							Yes
	AO6						No
							Yes
	AP6						No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	6	Wiley, S.R., <i>et al.</i> , Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis," <i>Immunity</i> 3:673-682, Cell Press (1995).
CK	AS	6	Zamai, L., <i>et al.</i> , "Natural killer (NK) Cell-mediated Cytotoxicity: Differential Use of TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells," <i>J. Exp. Med.</i> 188:2375-2380, Rockefeller University Press (December 1998).
CK	AT	6	NCBI Entrez, Genbank Report, Accession No. Z66083, from MacDonald, M., <i>et al.</i> (October 1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/SJE	APPLICATION NO. <i>To be assigned</i>
	FIRST NAMED INVENTOR Jian Ni	
	FILING DATE February 10, 2004	ART UNIT <i>To be assigned</i>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA7						
	AB7						
	AC7						
	AD7						
	AE7						
	AF7						
	AG7						
	AH7						
	AI7						
	AJ7						
	AK7						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL7						Yes No
	AM7						Yes No
	AN7						Yes No
	AO7						Yes No
	AP7						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	Z	NCBI Entrez, Genbank Report, Accession No. AA223122, from Hillier, L., <i>et al.</i> (February 1997).
CK	AS	Z	NCBI Entrez, Genbank Report, Accession No. AA232440, from Hillier, L., <i>et al.</i> (February 1997).
CK	AT	Z	Pending Non-Provisional United States Patent Application No.09/042,583, Ni <i>et al.</i> , filed March 17, 1998.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/SJE	APPLICATION NO. <i>To be assigned</i>
	FIRST NAMED INVENTOR Jian Ni	
	FILING DATE February 10, 2004	ART UNIT <i>To be assigned</i>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA8						
	AB8						
	AC8						
	AD8						
	AE8						
	AF8						
	AG8						
	AH8						
	AI8						
	AJ8						
	AK8						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL8						Yes No
	AM8						Yes No
	AN8						Yes No
	AO8						Yes No
	AP8						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	8	Pending Non-Provisional United States Patent Application No. 09/565,009, Ni <i>et al.</i> , filed May 4, 2000.
CK	AS	8	Pending Non-Provisional U.S. Patent Application No. 09/912,293, filed July 26, 2001, NOT PUBLISHED: pages 1-75 (pages 1 + 2 partially redacted); portion of Table 2; and SEQ ID NOs.: 7851 and 190763. -----DO NOT PRINT-----
CK	AT	8	Beutler, B., and Cerami, A., "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," <i>Ann. Rev. Biochem.</i> 57:505-518, Annual Reviews Inc. (1988).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/SJE	APPLICATION NO. <i>To be assigned</i>
	FIRST NAMED INVENTOR Jian Ni	
	FILING DATE February 10, 2004	ART UNIT <i>To be assigned</i>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA9						
	AB9						
	AC9						
	AD9						
	AE9						
	AF9						
	AG9						
	AH9						
	AI9						
	AJ9						
	AK9						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
	AL9						No
							Yes
	AM9						No
							Yes
	AN9						No
							Yes
	AO9						No
							Yes
	AP9						No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>9</u>	Fiers, W., "Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level," <i>FEBS Lett.</i> 285:199-212, Elsevier Science B.V. (1991).
CK	AS	<u>9</u>	Goeddel, D.V., et al., "Tumor Necrosis Factors: Gene Structure and Biological Activities," <i>Cold Spring Harb. Symp. Quant. Biol.</i> 51(Pt. 1):597-609, Cold Spring Harbor Laboratory Press (1986).
CK	AT	<u>9</u>	Golstein, P., "Cell death: TRAIL and its receptors," <i>Curr. Biol.</i> 7:R750-R753, Current Biology Ltd. (December 1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/SJE	APPLICATION NO. <i>To be assigned</i>
	FIRST NAMED INVENTOR Jian Ni	
	FILING DATE February 10, 2004	ART UNIT <i>To be assigned</i>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA10						
	AB10						
	AC10						
	AD10						
	AE10						
	AF10						
	AG10						
	AH10						
	AI10						
	AJ10						
	AK10						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL10						Yes No
	AM10						Yes No
	AN10						Yes No
	AO10						Yes No
	AP10						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>10</u>	Gruss, H.-J., and Dower, S.K., "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas," <i>Blood</i> 85:3378-3404, The American Society of Hematology (1995).
CK	AS	<u>10</u>	Locksley, R.M., <i>et al.</i> , "The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology," <i>Cell</i> 104:487-501, Cell Press (February 2001).
CK	AT	<u>10</u>	Nagata, S., "Apoptosis by Death Factor," <i>Cell</i> 88:355-365, Cell Press (February 1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/SJE	APPLICATION NO. <i>To be assigned</i>
	FIRST NAMED INVENTOR Jian Ni	
	FILING DATE February 10, 2004	ART UNIT <i>To be assigned</i>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA11						
	AB11						
	AC11						
	AD11						
	AE11						
	AF11						
	AG11						
	AH11						
	AI11						
	AJ11						
	AK11						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL11						Yes No
	AM11						Yes No
	AN11						Yes No
	AO11						Yes No
	AP11						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>11</u>	Old, L.J., "Tumor Necrosis Factor," <i>Scientific American</i> , pp. 59-75, Scientific American, Inc. (May 1988).
CK	AS	<u>11</u>	Wallach, D., "TNF Ligand and TNF/NGF Receptor Families," in <i>Cytokine Reference. A compendium of cytokines and other mediators of host defense</i> , Oppenheim, J.J., et al., eds., Academic Press, Inc., San Diego, CA, pp. 377-411 (August 2000).
CK	AT	<u>11</u>	Brojatsch, J., et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis," <i>Cell</i> 87:845-855, Cell Press (November 1996).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000D/EKS/EJH/SJEAPPLICATION NO.
*To be assigned*FIRST NAMED INVENTOR
Jian NIFILING DATE
February 10, 2004ART UNIT
*To be assigned***U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA12						
	AB12						
	AC12						
	AD12						
	AE12						
	AF12						
	AG12						
	AH12						
	AI12						
	AJ12						
	AK12						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
	AL12						No
	AM12						Yes
							No
	AN12						Yes
							No
	AO12						Yes
							No
	AP12						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	12	Chapman, B.S., "A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-I and Fas," <i>FEBS Lett.</i> 374:216-220, Elsevier (1995).
CK	AS	12	Rabizadeh, S., <i>et al.</i> , "Induction of Apoptosis by the Low-Affinity NGF Receptor," <i>Science</i> 261:345-348, American Association for the Advancement of Science (1993).
CK	AT	12	Tartaglia, L.A., <i>et al.</i> , "A Novel Domain within the 55 kd TNF Receptor Signals Cell Death," <i>Cell</i> 74:845-853, Cell Press (1993).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/SJE	APPLICATION NO. <i>To be assigned</i>
	FIRST NAMED INVENTOR Jian Ni	
	FILING DATE February 10, 2004	ART UNIT <i>To be assigned</i>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA13						
	AB13						
	AC13						
	AD13						
	AE13						
	AF13						
	AG13						
	AH13						
	AI13						
	AJ13						
	AK13						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL13						Yes No
	AM13						Yes No
	AN13						Yes No
	AO13						Yes No
	AP13						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>13</u>	Statutory Declaration of Avi J. Ashkenazi, signed March 14, 2003. -----DO NOT PRINT-----
CK	AS	<u>13</u>	Curriculum vitae of Avi Ashkenazi. -----DO NOT PRINT-----
CK	AT	<u>13</u>	Copy of provisional U.S. application 60/040,846, inventor Ni <i>et al.</i> , filed March 17, 1997.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000D/EKS/EJH/SJEAPPLICATION NO.
~~To be assigned~~ 10/774,622FIRST NAMED INVENTOR
Jian NiFILING DATE
February 10, 2004ART UNIT
~~To be assigned~~ 1646**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA14						
	AB14						
	AC14						
	AD14						
	AE14						
	AF14						
	AG14						
	AH14						
	AI14						
	AJ14						
	AK14						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
	AL14						No
	AM14						Yes
							No
	AN14						Yes
							No
	AO14						Yes
							No
	AP14						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	14	Copy of provisional U.S. application 60/054,021, inventor Ni <i>et al.</i> , filed July 29, 1997.
CK	AS	14	Copy of U.S. application 08/857,216, inventor Ashkenazi, filed May 15, 1997.
CK	AT	14	Statement of Grounds and Particulars filed in the opposition to Human Genome Sciences, Inc., Australian Patent Application 747635 (67635/98) by Genentech, Inc.

-----DO NOT PRINT-----

EXAMINER

/Claire Kaufman/

DATE CONSIDERED

09/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000D/EKS/EJH/M-MAPPLICATION NO.
10/774,622FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
February 10, 2004ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
CK	AD2	2002/0098550 A1	07/25/2002	Ni <i>et al.</i>	X		12/07/2001
	AE2	6,743,625	06/01/2004	Ni <i>et al.</i>			06/06/2001
	AF2	6,461,823	10/08/2002	Ni <i>et al.</i>			11/24/1999
	AG2	6,342,363	01/29/2002	Ni <i>et al.</i>			01/27/1998
CK	AH2	6,433,147	08/13/2002	Ni <i>et al.</i>			05/05/2000
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
CK	AL4	WO 98/41629 A2 & A3	09/24/1998	WIPO	X		Yes No
	AM4	EP 1 181 319 A0	12/07/2000	Europe			Yes No
	AN4	EP 1 192 185 A0	12/14/2000	Europe			Yes No
CK	AO4	EP 1 287 035 A1	03/05/2003	Europe			Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


CK	AR	15	Allison, J., <i>et al.</i> , "Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts," <i>Proc. Natl. Acad. Sci. USA</i> 94:3943-3947, National Academy Press (April 1997)
	AS	15	Allison, J., and Strasser, A., "Mechanisms of β cell death in diabetes: A minor role for CD95," <i>Proc. Natl. Acad. Sci. USA</i> 95:13818-13822, National Academy Press (November 1998)
CK	AT	15	Bodmer, J.-L., <i>et al.</i> , "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88, Cell Press (January 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Page 2 of 19	
<p style="text-align: center;">FORM PTO-1485</p> <p style="text-align: center;">FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</p>	<p>ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M</p> <p>FIRST NAMED INVENTOR Ni <i>et al.</i></p> <p>FILING DATE February 10, 2004</p> <p>APPLICATION NO. 10/774,622</p> <p>ART UNIT 1646</p>




U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes
	AM						No
	AN						Yes
	AO						No
	AP						Yes

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
CK	AR	16	Boldin, M.P., <i>et al.</i> , "A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain," <i>J. Biol. Chem.</i> 270:7795-7798, American Society for Biochemistry and Molecular Biology, Inc. (1995)
CK	AS	16	Chicheportiche, Y., <i>et al.</i> , "TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis," <i>J. Biol. Chem.</i> 272:32401-32410, American Society for Biochemistry and Molecular Biology, Inc. (December 1997)
CK	AT	16	Chinnaiyan, A.M., <i>et al.</i> , "FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis," <i>Cell</i> 81:505-512, Cell Press (1995)

EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>	

Page 3 of 19							
FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	<div style="text-align: center;">  </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M</td> <td style="width: 50%;">APPLICATION NO. 10/774,622</td> </tr> <tr> <td colspan="2">FIRST NAMED INVENTOR Ni <i>et al.</i></td> </tr> <tr> <td>FILING DATE February 10, 2004</td> <td>ART UNIT 1646</td> </tr> </table>	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622	FIRST NAMED INVENTOR Ni <i>et al.</i>		FILING DATE February 10, 2004	ART UNIT 1646
ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622						
FIRST NAMED INVENTOR Ni <i>et al.</i>							
FILING DATE February 10, 2004	ART UNIT 1646						

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
CK	AR	17	Clerici, M., <i>et al.</i> , "Type 1 and Type 2 Cytokines in HIV Infection - A Possible Role in Apoptosis and Disease Progression," <i>Ann. Med.</i> 29:185-188, Finnish Medical Society DUODECIM (June 1997)
CK	AS	17	Degli-Esposti, M.A., <i>et al.</i> , "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J. Exp. Med.</i> 186:1165-11170, Rockefeller University Press (October 1997)
CK	AT	17	Degli-Esposti, M.A., <i>et al.</i> , "The Novel Receptor TRAIL-R4 Induces NF- κ B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain," <i>Immunity</i> 7:813-820, Cell Press (December 1997)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	18	Duan, H. and Dixit, V.M., "RAIDD is a new 'death' adaptor molecule," <i>Nature</i> 385:86-89, Macmillan Publishers, Ltd. (January 1997)
CK	AS	18	Frankfurt, O.S., <i>et al.</i> , "Protection from Apoptotic Cell Death by Interleukin-4 is Increased in Previously Treated Chronic Lymphocytic Leukemia Patients," <i>Leuk. Res.</i> 21:9-16, Elsevier Science, Ltd (January 1997)
CK	AT	18	Gooch, J.L., <i>et al.</i> , "Interleukin 4 Inhibits Growth and Induces Apoptosis in Human Breast Cancer Cells," <i>Cancer Res.</i> 58:4199-4205, American Association for Cancer Research (September 1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	19	Grell, M., <i>et al.</i> , "Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF," <i>EMBO J.</i> 18:3034-3043, Oxford University Press (June 1999)
CK	AS	19	Hardiman, G., <i>et al.</i> , "Genetic Structure and Chromosomal Mapping of MyD88," <i>Genomics</i> 45:332-339, Academic Press (October 1997)
CK	AT	19	Hildeman, D.A., <i>et al.</i> , "Activated T Cell Death In Vivo Mediated by Proapoptotic Bcl-2 Family Member Bim," <i>Immunity</i> 16:759-767, Cell Press (June 2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	20	Hill, M.E., <i>et al.</i> , "Prognostic Significance of BCL-2 Expression and <i>bcl-2</i> Major Breakpoint Region Rearrangement in Diffuse Large Cell Non-Hodgkin's Lymphoma: A British National Lymphoma Investigation Study," <i>Blood</i> 88:1046-105, American Society of Hematology (August 1996)
CK	AS	20	Ho, Y.S., <i>et al.</i> , "Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer," <i>Nature</i> 385:89-93, Macmillan Publishers, Ltd. (January 1997)
CK	AT	20	Hofmann, K., and Bucher, P., "The CARD domain: a new apoptotic signalling motif," <i>Trends Biochem. Sci.</i> 22:155-156, Elsevier Science, Ltd. (May 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000D/EKS/EJH/M-MAPPLICATION NO.
10/774,622FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
February 10, 2004ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	21	Horigome, A., <i>et al.</i> , "Tacrolimus-induced apoptosis and its prevention by interleukins in mitogen-activated human peripheral-blood mononuclear cells," <i>Immunopharmacology</i> 39:21-30, Elsevier Science B.V. (March 1998)
CK	AS	21	Hsu, H., <i>et al.</i> , "TRADD-TRAF2 and TRADD-FADD Interactions Define Two Distinct TNF Receptor 1 Signal Transduction Pathways," <i>Cell</i> 84:299-308, Cell Press (January 1996)
CK	AT	21	Huang, D.C.S., <i>et al.</i> , "Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x _L ," <i>Proc. Natl. Acad. Sci. USA</i> 96:14871-14876, National Academy Press (December 1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes
	AM						No
	AN						Yes
	AO						No
	AP						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	22	Huang, D.C.S., <i>et al.</i> , "Bcl-2, Bcl-x _L and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death," <i>Oncogene</i> 14:405-414, Stockton Press (January 1997)
CK	AS	22	Irmler, M., <i>et al.</i> , "Direct physical interaction between the <i>Caenorhabditis elegans</i> 'death proteins' CED-3 and CED-4," <i>FEBS Lett.</i> 406:189-190, Elsevier Science B.V. (April 1997)
CK	AT	22	Irmler, M., <i>et al.</i> , "Inhibition of death receptor signals by cellular FLIP," <i>Nature</i> 388:190-195, Macmillan Publishers, Ltd. (July 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>23</u>	Karin, M., and Lin, A., "NF- κ B at the crossroads of life and death," <i>Nat. Immunol.</i> 3:221-227, Nature Publishing Group (March 2002)
CK	AS	<u>23</u>	Kelliher, M.A., <i>et al.</i> , "The Death Domain Kinase RIP Mediates the TNF-Induced NF- κ B Signal," <i>Immunity</i> 8:297-303, Cell Press (March 1998)
CK	AT	<u>23</u>	Lindner, H., <i>et al.</i> , "Peripheral Blood Mononuclear Cells Induce Programmed Cell Death in Human Endothelial Cells and May Prevent Repair: Role of Cytokines," <i>Blood</i> 89:1931-1938, American Society of Hematology (March 1997)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>24</u>	Lotem, J., and Sachs, L., "Hematopoietic Cytokines Inhibit Apoptosis Induced by Transforming Growth Factor β 1 and Cancer Chemotherapy Compounds in Myeloid Leukemic Cells," <i>Blood</i> 80:1750-1757, American Society of Hematology (1992)
CK	AS	<u>24</u>	Lotem, J., and Sachs, L., "Interferon- γ inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents and viability factor deprivation in myeloid cells," <i>Leukemia</i> 9:685-692, Stockton Press (1995)
CK	AT	<u>24</u>	MacFarlane, M., <i>et al.</i> , "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> 272:25417-25420, American Society for Biochemistry and Molecular Biology, Inc. (October 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	25	Muzio, M., <i>et al.</i> , "FLICE, a Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex," <i>Cell</i> 85:817-827, Cell Press (June 1996)
CK	AS	25	Muzio, M., <i>et al.</i> , "IRAK (Pelle) Family Member IRAK-2 and MyD88 as Proximal Mediators of IL-1 Signaling," <i>Science</i> 278:1612-1615, American Association for the Advancement of Science (November 1997)
CK	AT	25	Newton, K., <i>et al.</i> , "A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes," <i>EMBO J.</i> 17:706-718, Oxford Univeristy Press (February 1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>26</u>	Newton, K., <i>et al.</i> , "FADD/MORT1 regulates the pre-TCR checkpoint and can function as a tumour suppressor," <i>EMBO J.</i> 19:931-941, Oxford University Press (March 2000)
CK	AS	<u>26</u>	Newton, K., <i>et al.</i> , "Effects of a dominant interfering mutant of FADD on signal transduction in activated T cells," <i>Curr. Biol.</i> 11:273-276, Elsevier Science, Ltd. (February 2001)
CK	AT	<u>26</u>	Newton, K., and Strasser, A., "Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of Fas or FACC/MORT1 Signaling: Implications for Cancer Therapy," <i>J. Exp. Med.</i> 191:195-200, Rockefeller University Press (January 2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	27	O'Conner, L., <i>et al.</i> , "Fas, p53, and Apoptosis," <i>Science</i> 284:1431b, American Association for the Advancement of Science (May 1999)
CK	AS	27	O'Conner, L., <i>et al.</i> , "CD95 (Fas/APO-1) and p53 Signal Apoptosis Independently in Diverse Cell Types," <i>Cancer Res.</i> 60:1217-1220, American Association for Cancer Research (March 2000)
CK	AT	27	Odaka, C., <i>et al.</i> , "Immunosuppressant deoxyspergualin induces apoptotic cell death in dividing cells," <i>Immunol.</i> 95:370-376, Blackwell Science, Ltd. (November 1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>28</u>	Pan, G., <i>et al.</i> , "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," <i>FEBS Lett.</i> 424:41-45, Elsevier Science B.V. (March 1998)
CK	AS	<u>28</u>	Screaton, G.R., <i>et al.</i> , "LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-4619, National Academy Press (April 1997)
CK	AT	<u>28</u>	Shadmehr, R., and Holcomb, H.H., "Neural Correlates of Motor Memory Consolidation," <i>Science</i> 277:821-825, American Association for the Advancement of Science (August 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>29</u>	Simonitsch, I., and Krupitza, G., "Autocrine self-elimination of cultured ovarian cancer cells by tumour necrosis factor α (TNF- α)," <i>Br. J. Cancer</i> 78:862-870, Nature Publishing Group on behalf of Cancer Research, UK (October 1998)
CK	AS	<u>29</u>	Smith, K.G.C., <i>et al.</i> , "CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphodenopathy or autoimmune disease," <i>EMBO J.</i> 15:5167-5176, Oxford University Press (October 1996)
CK	AT	<u>29</u>	Strasser, A., <i>et al.</i> , "Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis," <i>EMBO J.</i> 14:6136-1647, Oxford University Press (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	1488.131000D/EKS/EJH/M-M	10/774,622
	FIRST NAMED INVENTOR	
	Ni <i>et al.</i>	
	FILING DATE	ART UNIT
	February 10, 2004	1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	<u>30</u>	Thome, M., <i>et al.</i> , "Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors," <i>Nature</i> 386:517-521, Macmillan Publishers, Ltd. (April 1997)
CK	AS	<u>30</u>	Villunger, A., <i>et al.</i> , "Fas Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and p38 Mitogen-activated Protein Kinase: Regulators of Distinct Cell Death and Survival Pathways in Granulocytes," <i>J. Exp. Med.</i> 192:647-657, Rockefeller University Press (September 2000)
CK	AT	<u>30</u>	Villunger, A., <i>et al.</i> , "Fas Ligand-Induced c-Jun Kinase Activation in Lymphoid Cells Requires Extensive Receptor Aggregation But Is Independent of DAXX, and Fas-Mediated Cell Death Does Not Involve DAXX, RIP, or RAIDD," <i>J. Immunol.</i> 165:1337-1343, American Association of Immunologists (August 2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	31	Walczak, H., <i>et al.</i> , "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> 16:5386-5397, Oxford University Press (September 1997)
CK	AS	31	Watanabe-Fukunaga, R., <i>et al.</i> , "Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis," <i>Nature</i> 356:314-317, Macmillan Publishers, Ltd. (1992)
CK	AT	31	Wong, B.B., <i>et al.</i> , "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells," <i>J. Biol. Chem.</i> 272:25190-25194, American Society for Biochemistry and Molecular Biology, Inc. (October 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni et al.	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
	AL						Yes
							No
	AM						Yes
							No
	AN						Yes
							No
	AO						Yes
							No
	AP						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	32	Yoshida, T., et al., "Rapid B cell apoptosis induced by antigen receptor ligation does not require Fas (CD95/APO-1), the adaptor protein FADD/MORT1 or CrmA-sensitive caspases but is defective in both MRL-+/+ and MRL-lpr/lpr mice," <i>Int. Immunol.</i> 12:517-526, Japanese Society for Immunology (April 2000)
CK	AS	32	Zou, W., et al., "Administration of Interleukin 13 to Simian Immunodeficiency Virus-Infected Macaques: Induction of Intestinal Epithelial Atrophy," <i>AIDS Res Hum Retroviruses</i> 14:775-793, Mary Ann Liebert, Inc. (June 1998)
CK	AT	32	European Search Report for European Application No. EP 00 93 0329 mailed on February 6, 2004, Munich, Germany

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000D/EKS/EJH/M-M	APPLICATION NO. 10/774,622
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE February 10, 2004	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

			Co-Pending U.S. Patent Application No. 10/005,842, inventors Ni <i>et al.</i> , filed December 7, 2001, now U.S. Published Patent Application No. 2002/0098550 (Document AD2)
	AR	33	DUPLICATE
CK	AS	33	Copy of co-pending U.S. Application No. 10/648,825, inventors Ni <i>et al.</i> , filed August 27, 2003, now U.S. Published Patent Application No. 2004/1036951
	AT		

EXAMINER /Claire Kaufman/

DATE CONSIDERED 09/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.